Floatz logo

Pidnarulex

Metastatic Hormone Receptor-Positive Breast Carcinoma

National Cancer Institute (NCI)Small moleculePhase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
89/ 100

Competitive context

116 Active assets in the Metastatic Hormone Receptor-Positive Breast Carcinoma cohort.

Asset / SponsorPhaseRating
Everolimus
Ellipses Pharma
Phase 4BBB
EXEMESTANE
Fujian Cancer Hospital
Phase 4BBB
Arimidex
University of Illinois at Chicago
Phase 4BBB
Ribociclib
BeOne Medicines
Phase 4BBB
Palbociclib
BeOne Medicines
Phase 3BBB

View all 50 →

Same molecule, other indications

Pidnarulex is also rated in:

colorectal cancerDormant
CCC
Indicative ·
48 / 100
View asset →
large B-cell lymphomaDormant
CC
Indicative ·
47 / 100
View asset →
high grade B-cell lymphoma with MYC and/ or BCL2 and/or BCL6 rearrangementDormant
CC
Indicative ·
45 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →